Amylin picks ex-Novartis exec as chairman

Amylin Pharmaceuticals has tapped Paulo Costa--who previously ran Novartis' U.S. operations--to head up its board. Release

Aureon Laboratories has promoted Robert Shovlin from president to president and chief executive officer. Vijay Aggarwal, Ph.D. will step down as CEO, but will remain a member of the company's board of directors. Release

VistaGen Therapeutics has appointed Shawn Singh as its chief executive. Release

Alnylam Pharmaceuticals announced that chief scientist John (Jack) Schmidt has resigned from the company. Release

RXi Pharmaceuticals announced that Stephen J. DiPalma has resigned as executive vice president of business operations and CFO to pursue other opportunities. Release

Achaogen has named John C. Doyle to the newly created position of chief operating officer. Release

LabConnect appointed Frank D. Morrow, Ph.D., FACN, as its chief operating officer. Release

Sutro Biopharma named Henry Heinsohn, former senior scientist in process development at Genentech, as vice president of development and manufacturing, and Lesley Stolz, Ph.D., former vice president, corporate and business development at Sunesis Pharmaceuticals, as vice president of business development. Daniel H. Petree of P2 Partners has been elected to the Sutro Biopharma board of directors. Release

Adamas Pharmaceuticals has expanded its management team, naming Michael D. Coffee, senior vice president, sales and marketing, and Amy K. Patick, Ph.D., vice president, research. Release

Orexigen Therapeutics announced that Mark Booth has joined the company as chief commercial officer. Release

Xcelience has hired Brett F. Truitt, who will serve as team leader, formulation development in the Pharmaceutical Development Services division. Release

Catalent Pharma Solutions named Scott Houlton as group president for a new business unit dedicated to helping customers bring new pharmaceutical and biologic products to market. Release

NeurogesX has named Bradford S. Goodwin to its board of directors as a director and Audit Committee chairman. Release

Repligen Corporation announced that Glenn L. Cooper, M.D. has been elected to its Board of Directors. Release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.